文献速递糖尿病肥胖与代谢综合征

HOMA-IR用于诊断非酒精性脂肪性肝病:基于人群和实验室间研究

Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study.
PubMed 文献 · Diabetologia · 2017-06-29

在FINRISK 2007和FIN-D2D两个人群队列的健康个体中确定HOMA-IR正常上限,并在368名非糖尿病个体中确定NAFLD的最佳HOMA-IR切点;健康人群HOMA-IR第95百分位数为1.9和2.0,NAFLD最佳切点为1.9(敏感性87%,特异性79%),七家欧洲实验室间HOMA-IR变异系数为25%,主要源于胰岛素检测差异。

要点

  • 健康人群HOMA-IR第95百分位数为FINRISK队列1.9、FIN-D2D队列2.0。
  • NAFLD最佳HOMA-IR切点为1.9,敏感性87%,特异性79%。
  • HOMA-IR为2.0对应正常肝脏脂肪(1H-MRS<5.56%)。

核心结论

  • 人群队列中HOMA-IR正常上限与正常肝脏脂肪对应的HOMA-IR值密切吻合。
  • 标准化胰岛素检测是定义HOMA-IR正常值的第一步。

研究设计与样本

  • 在FINRISK 2007(n=5024)和FIN-D2D(n=2849)两个人群队列中识别健康个体以确定HOMA-IR第95百分位数。
  • 在368名非糖尿病个体(35%患NAFLD)中,用质子磁共振波谱(1H-MRS)测肝脏脂肪,确定NAFLD最佳HOMA-IR切点。
  • 来自十名个体的样本在七家欧洲实验室同时检测HOMA-IR。

主要发现

  • FINRISK队列健康个体(n=1167)HOMA-IR第95百分位数为1.9,FIN-D2D队列健康个体(n=459)为2.0。
  • 性别或PNPLA3 rs738409基因型不影响上述HOMA-IR值。
  • NAFLD最佳HOMA-IR切点为1.9(敏感性87%,特异性79%)。
  • 线性回归分析中HOMA-IR 2.0对应正常肝脏脂肪(1H-MRS<5.56%)。
  • 赫尔辛基测得的HOMA-IR 2.0在其他六家实验室分别对应1.3、1.6、1.8、1.8、2.0和2.1。

关键数值与推荐

  • 健康个体HOMA-IR第95百分位数:FINRISK队列1.9,FIN-D2D队列2.0。
  • NAFLD最佳HOMA-IR切点1.9,敏感性87%,特异性79%。
  • HOMA-IR 2.0对应正常肝脏脂肪(1H-MRS<5.56%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Recent European guidelines for non-alcoholic fatty liver disease (NAFLD) call for reference values for HOMA-IR. In this study, we aimed to determine: (1) the upper limit of normal HOMA-IR in two population-based cohorts; (2) the HOMA-IR corresponding to NAFLD; (3) the effect of sex and PNPLA3 genotype at rs738409 on HOMA-IR; and (4) inter-laboratory variations in HOMA-IR. METHODS: We identified healthy individuals in two population-based cohorts (FINRISK 2007 [n = 5024] and the Programme for Prevention of Type 2 Diabetes in Finland [FIN-D2D; n = 2849]) to define the upper 95th percentile of HOMA-IR. Non-obese individuals with normal fasting glucose levels, no excessive alcohol use, no known diseases and no use of any drugs were considered healthy. The optimal HOMA-IR cut-off for NAFLD (liver fat ≥5.56%, based on the Dallas Heart Study) was determined in 368 non-diabetic individuals (35% with NAFLD), whose liver fat was measured using proton magnetic resonance spectroscopy (1H-MRS). Samples from ten individuals were simultaneously analysed for HOMA-IR in seven European laboratories. RESULTS: The upper 95th percentiles of HOMA-IR were 1.9 and 2.0 in healthy individuals in the FINRISK (n = 1167) and FIN-D2D (n = 459) cohorts. Sex or PNPLA3 genotype did not influence these values. The optimal HOMA-IR cut-off for NAFLD was 1.9 (sensitivity 87%, specificity 79%). A HOMA-IR of 2.0 corresponded to normal liver fat (<5.56% on 1H-MRS) in linear regression analysis. The 2.0 HOMA-IR measured in Helsinki corresponded to 1.3, 1.6, 1.8, 1.8, 2.0 and 2.1 in six other laboratories. The inter-laboratory CV% of HOMA-IR was 25% due to inter-assay variation in insulin (25%) rather than glucose (5%) measurements. CONCLUSIONS/INTERPRETATION: The upper limit of HOMA-IR in population-based cohorts closely corresponds to that of normal liver fat. Standardisation of insulin assays would be the first step towards definition of normal values for HOMA-IR.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Isokuortti E, Zhou Y, Peltonen M, et al. Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. Diabetologia. 2017. PMID: 28660493. doi:10.1007/s00125-017-4340-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。